Answers are grounded in this paper and cite their sources.
The utility of blinded sample size re-estimation for clinical trials depends on the ability to estimate variability without providing information about the true treatment difference, and on some reasonable assurance that the method is not likely to cause the sample size to be increased when the treatment effect is better than anticipated. We show that violations of these properties are unlikely to occur in practice.
No takes yet. Share an insight, caveat, or question.
A. Lawrence Gould (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: